Stem Cell Therapy in Korea: What’s Legal, What’s New

South Korea has one of the most advanced and well-regulated stem cell therapy landscapes in the world. It’s also one of the most confusing, because the gap between what’s legally approved, what’s in clinical trials, and what’s marketed to desperate patients on the internet is vast.

Korea approved the world’s first stem cell drug (Hearticellgram-AMI for heart attack recovery) in 2011. It has the world’s largest Catholic hospital-based stem cell center at Seoul St. Mary’s Hospital. Its regulatory framework is more permissive than the US FDA’s, allowing conditional approval of cell therapies based on Phase II data. And yet, many of the “stem cell clinics” that market to international patients online operate in legal gray areas or outright fraud.

This guide separates what’s real from what’s not. It covers legally approved stem cell treatments in Korea, active clinical trials worth knowing about, the role of Seoul St. Mary’s Hospital, realistic cost expectations, and how to identify and avoid scams.

Korea’s Regulatory Framework for Stem Cells

Understanding how Korea regulates stem cell therapy explains why it’s further ahead than the US in some areas, and why that doesn’t mean everything labeled “stem cell therapy” is legitimate.

MFDS (Korean FDA) Classification

Korea’s Ministry of Food and Drug Safety (MFDS) classifies cell therapies into three categories:

1. Approved Cell Therapy Products. These have completed clinical trials and received marketing authorization from MFDS. They are manufactured under GMP conditions and can be administered at any licensed medical facility.

2. Conditionally Approved Products. Korea’s conditional approval pathway allows cell therapies to reach patients after Phase II clinical trials (demonstrating safety and preliminary efficacy), with continued Phase III monitoring. This is faster than the US FDA pathway, which typically requires completed Phase III trials.

3. Clinical Trial Therapies. Experimental stem cell treatments available only within registered clinical trials at approved sites. Patients must meet eligibility criteria and consent to the trial protocol.

How This Compares to the US

The US FDA regulates stem cells under a strict framework:

• Autologous cells that are “minimally manipulated” and used for “homologous use” (e.g., bone marrow transplant for blood cancer) are regulated as medical procedures, not drugs.
• Any cell therapy involving more than minimal manipulation (expansion, differentiation, genetic modification) is regulated as a biological drug under CBER, requiring full IND/BLA approval.
• The FDA has shut down hundreds of clinics offering unapproved stem cell therapies in the US.

Korea’s conditional approval system means patients can access some therapies 3-5 years earlier than they would in the US. This is the legitimate reason to consider Korea for stem cell treatment, not because regulations are lax, but because the approval pathway is structured differently.

Legally Approved Stem Cell Treatments in Korea

As of 2025, the following cell and stem cell therapy products have received MFDS approval or conditional approval:

1. Hearticellgram-AMI (Autologous Bone Marrow Stem Cells for Heart Attack)

• Manufacturer: Pharmicell
• Approved: 2011 (world’s first approved stem cell drug)
• What it is: Autologous mesenchymal stem cells harvested from the patient’s bone marrow, expanded in culture, and injected into damaged heart tissue after acute myocardial infarction
• Evidence: Improved left ventricular function in clinical trials
• Availability: Limited to specific cardiac centers

2. Cupistem (Autologous Adipose Stem Cells for Crohn’s Fistula)

• Manufacturer: Anterogen
• Approved: 2012
• What it is: Adipose-derived stem cells injected into anal fistulas in Crohn’s disease patients
• Evidence: Higher fistula closure rates than conventional treatment
• Note: Similar concept to Alofisel (approved in EU 2018, not in US)

3. Cartistem (Allogeneic Cord Blood Stem Cells for Cartilage Repair)

• Manufacturer: Medipost
• Approved: 2012
• What it is: Umbilical cord blood-derived mesenchymal stem cells combined with hyaluronic acid, implanted into knee cartilage defects during arthroscopic surgery
• Target: Grade 3-4 cartilage lesions in the knee (focal defects, not diffuse osteoarthritis)
• Evidence: Cartilage regeneration demonstrated on MRI and histology
• Availability: Widely available at major orthopedic centers
• Cost: $10,000-$15,000 including surgery

4. Neuronata-R (Autologous Bone Marrow MSCs for ALS)

• Manufacturer: Corestem
• Approved: 2014 (conditional)
• What it is: Autologous bone marrow mesenchymal stem cells for amyotrophic lateral sclerosis (Lou Gehrig’s disease)
• Evidence: Slowed disease progression in some patients in Phase II trials. Conditional approval requires ongoing data collection.
• Important caveat: ALS remains incurable. This therapy may slow progression but is not a cure. Claims of ALS reversal from any source are not supported by evidence.

5. Bone Marrow Transplantation (Hematopoietic Stem Cell Transplant)

While not a “stem cell product” in the same regulatory sense, bone marrow transplant (BMT) is the most established and important stem cell therapy in medicine. Korea is a global leader:

• Seoul St. Mary’s Hospital has performed over 6,000 hematopoietic stem cell transplants, the most in Korea and ranked #5 globally for BMT volume.
• Used for: leukemia, lymphoma, multiple myeloma, aplastic anemia, sickle cell disease
• Success rates comparable to or exceeding US transplant centers
• Cost: $80,000-$150,000 in Korea vs. $300,000-$800,000+ in the US

Seoul St. Mary’s Hospital: Korea’s Cell Therapy Hub

Seoul St. Mary’s Hospital, the flagship of the Catholic University of Korea hospital system, operates the Catholic Hematopoietic Stem Cell Transplantation Center and the broader Cell Therapy Center. These are separate but related entities:

Hematopoietic Stem Cell Transplant Center

• Volume: 400+ transplants per year
• Cumulative: 6,000+ transplants performed
• Global ranking: #5 for transplant volume (Worldwide Network for Blood and Marrow Transplantation data)
• Specialties: Haploidentical transplant (half-matched family donors), cord blood transplant, reduced-intensity conditioning regimens for older patients
• Innovation: St. Mary’s developed techniques for haploidentical transplant that have been adopted internationally, expanding the donor pool for patients without matched donors
• Outcomes: Overall survival rates comparable to MD Anderson, Memorial Sloan Kettering, and Fred Hutchinson

Cell Therapy Center

• Houses GMP-grade cell processing facilities
• Conducts clinical trials for novel cell therapies (CAR-T, MSC therapies, iPSC-derived products)
• Partners with Pharmicell, Medipost, and other Korean biotech companies on translational research

Why St. Mary’s Matters for International Patients

For blood cancers (leukemia, lymphoma, myeloma), Seoul St. Mary’s is genuinely world-class, not “good for Asia” or “good for the price,” but among the best transplant centers on the planet. The combination of clinical expertise, transplant volume, advanced techniques (haploidentical, cord blood), and cost (roughly 70-80% less than US centers) makes it the most compelling option for patients who need BMT and face six-figure bills in the US.

What’s in Clinical Trials (Not Yet Approved)

These therapies are being studied in Korea but are NOT yet approved for routine clinical use. They’re available only through enrollment in registered clinical trials:

Parkinson’s Disease

Multiple Korean institutions are trialing dopaminergic neuron transplants derived from induced pluripotent stem cells (iPSCs) and embryonic stem cells. The goal is to replace the dopamine-producing neurons lost in Parkinson’s. Early-phase trials show safety and some functional improvement, but this is years from routine clinical availability.

Spinal Cord Injury

Korea has ongoing trials using mesenchymal stem cells and neural progenitor cells for spinal cord injury. Results are mixed. Some patients show neurological improvement, but the field has not yet produced a reliably effective treatment. Any clinic claiming to “cure” spinal cord injury with stem cells is not credible.

Heart Failure

Building on the Hearticellgram platform, Korean researchers are testing next-generation cardiac cell therapies including cardiac progenitor cells and engineered heart patches. These are in Phase I-II trials.

Osteoarthritis

Beyond Cartistem (which treats focal cartilage defects), several Korean trials are testing injectable MSC therapies for diffuse knee osteoarthritis, the much more common condition. Results are promising but not yet sufficient for approval. This is the area most likely to produce a new approved product in the next 3-5 years.

Stroke Recovery

MSC therapies for post-stroke neurological recovery are in trials at several Korean centers including Severance Hospital and Seoul National University Hospital. The concept is that MSCs can reduce inflammation and promote neural repair in the weeks to months after a stroke.

Cost of Stem Cell Therapy in Korea

How to Avoid Stem Cell Therapy Scams

This is the critical section. The global stem cell tourism market is rife with fraud, false hope, and genuine danger. Korea is not immune.

Red Flags That Indicate a Scam or Dangerous Practice

1. “We can treat any condition with stem cells.” No legitimate center makes this claim. Approved stem cell therapies are disease-specific. A clinic that claims to treat Alzheimer’s, autism, cerebral palsy, and anti-aging with the same stem cell injection is not practicing evidence-based medicine.

2. No clinical trial registration. If the treatment is experimental, it should be registered on ClinicalTrials.gov or the Korean Clinical Research Information Service (CRIS). Ask for the trial registration number. If they can’t provide one, the treatment is operating outside the regulatory framework.

3. Claims of guaranteed results. Stem cell therapy, even approved therapies, has variable outcomes. Any guarantee of cure or specific improvement is a red flag.

4. Extremely high prices with no transparent breakdown. Predatory clinics often charge $30,000-$100,000+ for unapproved IV stem cell infusions that cost very little to produce.

5. Aggressive marketing to international patients. Legitimate Korean hospitals have international patient departments. They do not typically run aggressive social media campaigns promising miracle cures.

6. No physician consultation before treatment. Legitimate cell therapy requires thorough medical evaluation, diagnostic workup, and informed consent with clear discussion of risks and realistic expectations.

7. “Stem cell IV infusions” for anti-aging or general wellness. There is no MFDS-approved stem cell product for anti-aging. IV infusions of MSCs for “rejuvenation” are not evidence-based and carry risks including pulmonary embolism (cells lodging in lung capillaries).

Where to Verify Legitimacy

• MFDS approved products list: Check whether the specific product has marketing authorization
• Korean Clinical Research Information Service (CRIS): cris.nih.go.kr, to search for registered clinical trials
• ClinicalTrials.gov: US-based registry that includes many Korean trials
• Korean Society for Stem Cell Research: Professional society for legitimate researchers
• Hospital affiliation: Is the treating physician affiliated with a recognized university hospital?

Safe Options for International Patients

If you’re considering stem cell therapy in Korea, here are the legitimate pathways:

1. MFDS-approved products (Cartistem, Hearticellgram, etc.) at licensed hospitals
2. Bone marrow transplant at established transplant centers like Seoul St. Mary’s or Severance
3. Clinical trial enrollment at registered trial sites (you’ll need to meet eligibility criteria)
4. Consultation with a Korean specialist who can evaluate your specific condition and advise whether any legitimate stem cell option exists for you

We do NOT facilitate connections to unregistered or unapproved stem cell clinics. If a treatment sounds too good to be true, it is.

The Future of Stem Cells in Korea

Korea is positioning itself as a global leader in cell therapy, and the pipeline is substantial:

• CAR-T cell therapy: Korean companies (including Curocell and GC Cell) are developing CAR-T therapies for blood cancers, following the success of Kymriah and Yescarta in the US. These may reach Korean patients at significantly lower cost than the $373,000-$475,000 US price tag.
• iPSC-derived therapies: Induced pluripotent stem cells (adult cells reprogrammed to an embryonic-like state) are being developed for Parkinson’s, macular degeneration, and heart disease.
• Exosome therapies: Cell-free approaches using the signaling molecules (exosomes) secreted by stem cells, without the cells themselves. Lower risk profile, potentially easier manufacturing.
• 3D bioprinting: Korean researchers are working on bioprinted tissue constructs for cartilage, bone, and skin repair.

The regulatory environment, research infrastructure, and manufacturing capability are all in place. Korea is likely to produce several new approved cell therapies in the next 5-10 years, and international patients who establish relationships with Korean medical centers now will have early access to these treatments as they become available.

How We Can Help

InKoreaNow works with Seoul St. Mary’s Hospital, Severance Hospital, and Korea University Anam Hospital, institutions at the forefront of legitimate stem cell research and treatment. We can help you:

• Determine whether an approved stem cell therapy exists for your condition
• Coordinate consultations with relevant specialists
• Evaluate clinical trial eligibility
• Arrange bone marrow transplant evaluations at Seoul St. Mary’s
• Work through the process of getting second opinions on treatment plans

We are not brokers for unapproved therapies. We connect patients with real doctors at real hospitals doing real medicine.

Share your diagnosis and medical records, and we’ll tell you honestly whether Korea has a legitimate treatment option for you.

Talk to Our Team →